<DOC>
	<DOCNO>NCT02031445</DOCNO>
	<brief_summary>Randomized , double-blind , parallel group , placebo-controlled , multicenter , efficacy safety study subject mild moderate atopic dermatitis . Following double blind period , subject allow continue treatment topical MRX-6 Cream 2 % open-label extension . Demonstrate efficacy MRX-6 Cream 2 % compare Vehicle treatment sign symptom atopic dermatitis demonstrate safety MRX-6 Cream 2 % treatment sign symptom atopic dermatitis .</brief_summary>
	<brief_title>Double-Blind , Trial Evaluate Safety Efficacy MRX-6 Cream 2 %</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subjects , ≥2 year age ≤17 year age , race ethnicity Must clinical diagnosis mild moderate atopic dermatitis ( AD ) Screening Baseline Visits , define IGA score 2 3 ( Hanifin Rajka , Rothe 1980 ) Must AD affect ≥ 5 % total body surface area ( TBSA ) Baseline History AD least 3 month prior Baseline Informed consent/assent accordance International Conference Harmonization ( ICH ) Good Clinical Practice ( GCP ) Guideline ( 21 CFR §50.25 [ c ] ) applicable regulation , complete studyrelated procedure Use topical corticosteroid within 7 day prior Baseline Use systemic corticosteroid , topical calcineurin inhibitor , phototherapy ( eg , PUVA , UVB ) immunosuppressive therapy ( eg , cyclosporine ) within 14 day prior Baseline Subjects require systemic therapy treatment atopic dermatitis Use systemic antiinfective antibiotic treatment within 14 day prior Baseline Subjects present clinical condition AD may interfere evaluation ( eg , generalized erythroderma , acne , Netherton 's Syndrome , psoriasis ) Secondary infection AD ( bacterial , viral fungal ) within skin area study open skin infection area Baseline Women childbearing potential lactating pregnant determine urine pregnancy test Screening . • History MRX6 cream 2 % sensitivity component test article History severe anxiety and/or depression ; history suicide attempt Subjects history human immunodeficiency virus ( HIV ) determine medical history Subjects screen clinical laboratory result outside normal range clinically relevant opinion appropriately qualified physician Subjects , opinion Investigator , would non compliant visit schedule study procedure Participation investigational trial within 6 week Baseline , study conduct Chronic condition ( ) either unstable adequately control Use nonsedating antihistamine within 7 day first dose time study conduct Drug alcohol abuse , mental dysfunction , condition limit subject 's ability compliant studyrelated procedure</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>